505 related articles for article (PubMed ID: 31771653)
41. Non-immune cell components in tumor microenvironment influencing lung cancer Immunotherapy.
Zhang J; Liu S; Chen X; Xu X; Xu F
Biomed Pharmacother; 2023 Oct; 166():115336. PubMed ID: 37591126
[TBL] [Abstract][Full Text] [Related]
42. Pharmaceutical targeting Th2-mediated immunity enhances immunotherapy response in breast cancer.
Chen Y; Sun J; Luo Y; Liu J; Wang X; Feng R; Huang J; Du H; Li Q; Tan J; Ren G; Wang X; Li H
J Transl Med; 2022 Dec; 20(1):615. PubMed ID: 36564797
[TBL] [Abstract][Full Text] [Related]
43. Novel Treatment Options in Metastatic Esophageal Carcinoma: Checkpoint Inhibitors in Combination Therapies.
Casari C; Novysedlak R; Vachtenheim J; Lischke R; Strizova Z
Pharmacology; 2023; 108(1):37-46. PubMed ID: 36463853
[TBL] [Abstract][Full Text] [Related]
44. Novel Immune Checkpoints in Esophageal Cancer: From Biomarkers to Therapeutic Targets.
Zhou X; Ren T; Zan H; Hua C; Guo X
Front Immunol; 2022; 13():864202. PubMed ID: 35669786
[TBL] [Abstract][Full Text] [Related]
45. Immunologic function of dendritic cells in esophageal cancer.
Yang W; Yu J
Dig Dis Sci; 2008 Jul; 53(7):1739-46. PubMed ID: 18080193
[TBL] [Abstract][Full Text] [Related]
46. A fibroblast-associated signature predicts prognosis and immunotherapy in esophageal squamous cell cancer.
Ren Q; Zhang P; Zhang X; Feng Y; Li L; Lin H; Yu Y
Front Immunol; 2023; 14():1199040. PubMed ID: 37313409
[TBL] [Abstract][Full Text] [Related]
47. The Novel Tumor Microenvironment-Related Prognostic Gene AIF1 May Influence Immune Infiltrates and is Correlated with TIGIT in Esophageal Cancer.
Xu X; Wang D; Li N; Sheng J; Xie M; Zhou Z; Cheng G; Fan Y
Ann Surg Oncol; 2022 May; 29(5):2930-2940. PubMed ID: 34751872
[TBL] [Abstract][Full Text] [Related]
48. Proliferation potential-related protein, an ideal esophageal cancer antigen for immunotherapy, identified using complementary DNA microarray analysis.
Yoshitake Y; Nakatsura T; Monji M; Senju S; Matsuyoshi H; Tsukamoto H; Hosaka S; Komori H; Fukuma D; Ikuta Y; Katagiri T; Furukawa Y; Ito H; Shinohara M; Nakamura Y; Nishimura Y
Clin Cancer Res; 2004 Oct; 10(19):6437-48. PubMed ID: 15475430
[TBL] [Abstract][Full Text] [Related]
49. CD8
Farhood B; Najafi M; Mortezaee K
J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
[TBL] [Abstract][Full Text] [Related]
50. Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors?
Nebot-Bral L; Coutzac C; Kannouche PL; Chaput N
Bull Cancer; 2019 Feb; 106(2):105-113. PubMed ID: 30342749
[TBL] [Abstract][Full Text] [Related]
51. A novel and robust pyroptosis-related prognostic signature predicts prognosis and response to immunotherapy in esophageal squamous cell carcinoma.
Zhang D; Zhao F; Li J; Qin X; Li S; Niu R
Aging (Albany NY); 2023 Aug; 15(15):7811-7830. PubMed ID: 37561524
[TBL] [Abstract][Full Text] [Related]
52. Perioperative immunotherapy for esophageal squamous cell carcinoma: Now and future.
Liu Y
World J Gastroenterol; 2023 Sep; 29(34):5020-5037. PubMed ID: 37753366
[TBL] [Abstract][Full Text] [Related]
53. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
[TBL] [Abstract][Full Text] [Related]
54. Inhibition of integrin αvβ6 sparks T-cell antitumor response and enhances immune checkpoint blockade therapy in colorectal cancer.
Busenhart P; Montalban-Arques A; Katkeviciute E; Morsy Y; Van Passen C; Hering L; Atrott K; Lang S; Garzon JFG; Naschberger E; Hartmann A; Rogler G; Stürzl M; Spalinger MR; Scharl M
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35131862
[TBL] [Abstract][Full Text] [Related]
55. Cellular therapy approaches harnessing the power of the immune system for personalized cancer treatment.
Bastien JP; Minguy A; Dave V; Roy DC
Semin Immunol; 2019 Apr; 42():101306. PubMed ID: 31604534
[TBL] [Abstract][Full Text] [Related]
56. Regulatory T cells in gastrointestinal tumors.
Raghavan S; Quiding-Järbrink M
Expert Rev Gastroenterol Hepatol; 2011 Aug; 5(4):489-501. PubMed ID: 21780896
[TBL] [Abstract][Full Text] [Related]
57. The effectivity of targeted therapy and immunotherapy in patients with advanced metastatic and non-metastatic cancer of the esophagus and esophago-gastric junction.
Valkema MJ; Mostert B; Lagarde SM; Wijnhoven BPL; van Lanschot JJB
Updates Surg; 2023 Feb; 75(2):313-323. PubMed ID: 35836094
[TBL] [Abstract][Full Text] [Related]
58. Clinical Significance of
Zhang N; Liu Y; Yang H; Liang M; Wang X; Wang M; Kong J; Yuan X; Zhou F
Pathol Oncol Res; 2021; 27():1609846. PubMed ID: 34305476
[TBL] [Abstract][Full Text] [Related]
59. Identification of an immune checkpoint gene signature that accurately predicts prognosis and immunotherapy response in endometrial carcinoma.
Li S; Dong C; Chen J; Gao X; Xie X; Zhang X
Aging (Albany NY); 2021 Jun; 13(12):16696-16712. PubMed ID: 34158412
[TBL] [Abstract][Full Text] [Related]
60. Immunotherapy for Esophageal and Gastric Cancer.
Kelly RJ
Am Soc Clin Oncol Educ Book; 2017; 37():292-300. PubMed ID: 28561677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
